Recent Updates — IRTC
iRhythm Holdings, Inc. completed its previously announced acquisition of Vital Connect, Inc., a leader in wearable biosensor technology and ambulatory cardiac monitoring. The transaction consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet, plus up to 423,334 shares issued at closing. Additionally, iRhythm provided $10.0 million of working capital funding between signing and closing. The acquisition expands iRhythm’s cardiac monitoring portfolio into inpatient and hospital-to-home settings, adding mobile cardiac telemetry capabilities. The deal is expected to enhance revenue growth starting in 2027 while preserving the company's adjusted EBITDA margin target of 15% for that year. iRhythm will provide updated financial guidance inclusive of VitalConnect during its third-quarter earnings call on November 5, 2026. iRhythm is a leading digital health care company specializing in wearable biosensors and cloud-based data analytics for cardiac monitoring.
iRhythm Holdings, Inc. announced that the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act occurred on September 18, 2026, for its proposed acquisition of Vital Connect, Inc. The transaction involves iRhythm Technologies, a wholly owned subsidiary, merging Merger Sub with Target, which will survive as a wholly owned subsidiary. The acquisition is anticipated to close in early October 2026, subject to customary closing conditions. This development removes the primary regulatory hurdle for the strategic expansion into adjacent healthcare markets. iRhythm Holdings operates in the medical technology industry and develops cardiac monitoring solutions.
On August 11, 2026, Brian Yoor notified iRhythm Holdings, Inc. of his resignation from the Board of Directors and as chair of the Audit Committee, effective August 12, 2026. The departure was for personal reasons and not due to disagreements regarding operations or policies. Karen McGinnis has been appointed as the new chair of the Audit Committee, also effective August 12, 2026. iRhythm Holdings, Inc. operates in the medical technology industry, specializing in ambulatory cardiac monitoring solutions.
On August 5, 2026, iRhythm Holdings, Inc. entered into an Agreement and Plan of Merger to acquire Vital Connect, Inc. The transaction involves aggregate consideration consisting of $237.5 million in cash and shares of iRhythm common stock valued at $50 million. Outstanding Target options will be cancelled without consideration, while vested and in-the-money warrants are eligible for equity consideration. An interim funding agreement provides up to $30.0 million in pre-closing operational support, with an initial $10.0 million grant. The acquisition is expected to close by the end of 2026, subject to stockholder approval and Hart-Scott-Rodino antitrust clearance. iRhythm operates in the digital health industry, developing wearable cardiac monitoring devices.
iRhythm Holdings, Inc. reported a material cybersecurity incident involving unauthorized activity in third-party-hosted business applications on June 8, 2026. A threat actor claimed to have exfiltrated sensitive information, including proprietary data and patient protected health information, and demanded payment to prevent disclosure. The company determined the incident is material, though it has not identified any impact to its clinical, medical device systems, or financial reporting systems. iRhythm Holdings, Inc. is a healthcare technology company providing cardiac monitoring services.